A cross-sectional study of 94 young Swiss men found that those with confirmed cannabis use had significantly higher levels of gonadal androgens, including testosterone, androstenedione, and dihydrotestosterone, compared to matched controls. While these findings offer the most comprehensive hormonal snapshot of cannabis-exposed young men to date, the study design cannot establish whether cannabis caused these hormonal differences or what they mean for long-term health.

Cannabis use among young men of reproductive age continues to rise, yet our understanding of its hormonal footprint has been limited to narrow testosterone assays and conflicting population-level findings. This study pushes the conversation forward by profiling 70 steroids simultaneously, revealing patterns that single-hormone measurements would miss entirely. Clinicians counseling patients on cannabis and fertility, mood, or metabolic health need to understand both the scope and the sharp limitations of these new data. The question of whether cannabis genuinely alters male hormonal physiology, or simply correlates with it, remains a pressing clinical and public health concern.

Prior research on cannabis and testosterone has produced mixed results, with some large Scandinavian and American cohort studies suggesting modestly higher testosterone in cannabis users and others finding no clear effect. The difficulty has been methodological: most prior work relied on self-reported exposure and measured only one or two hormones. This Swiss study, drawing from a military enrollment biobank spanning 2005 to 2017, applies liquid chromatography tandem mass spectrometry to profile 171 steroid targets, of which 70 were reliably detected. Cannabis exposure was confirmed by dual biomarker measurement (serum THC and THC-COOH) alongside self-report, strengthening the classification of users and controls relative to studies that depend on questionnaires alone.

The principal findings are a broad elevation of gonadal androgens, with androstenedione, testosterone, and dihydrotestosterone among the most significantly increased steroids in the 47 cannabis consumers compared to 47 matched controls. Notably, C11-oxyandrogens, which serve as markers of adrenal androgen production, were not significantly altered, leading the authors to infer a gonad-selective rather than adrenal hormonal perturbation. Two progesterone metabolites were also markedly elevated: 11-beta-hydroxyprogesterone across all cannabis users and 5-beta-dihydroprogesterone in a dose-dependent fashion correlating with THC-COOH levels. However, the cross-sectional design at a single time point, the small and demographically restricted sample, and the absence of longitudinal follow-up mean that causality, temporality, and generalizability cannot be established. The authors themselves note that replication in larger, more diverse cohorts with repeated measurements is essential.

This is exactly the kind of study I want to see more of in cannabis endocrinology: a wide-angle lens on steroid metabolism rather than the narrow testosterone snapshot we have been stuck with for decades. The dual-biomarker exposure confirmation is a real methodological step forward, and the identification of progesterone metabolite patterns is genuinely novel. That said, the gap between these associations and any clinical certainty is enormous. Forty-seven cannabis users, all young Swiss men from a military cohort, at a single blood draw, is not a foundation on which to build treatment recommendations. We cannot tell whether cannabis elevated these hormones, whether men with naturally higher androgens are more inclined to use cannabis, or whether an unmeasured confounder is driving both.

In practice, when a young male patient asks me whether cannabis will affect his hormones, I discuss the honest uncertainty. I explain that several studies, including this one, point toward higher androgen levels in users, not lower, which often surprises patients who have heard the opposite. But I am clear that this does not mean cannabis is beneficial for hormonal health, and I do not adjust any endocrine monitoring specifically because of cannabis use unless clinical symptoms suggest otherwise. This study is a roadmap for future research, not a clinical directive.

This study sits squarely in the hypothesis-generating phase of the research arc on cannabis and male reproductive endocrinology. It extends prior work by showing that the testosterone signal observed in larger epidemiological studies is not isolated but rather part of a broader gonadal androgen signature that includes androstenedione and dihydrotestosterone. The selective sparing of C11-oxyandrogens provides an intriguing pathway clue, but this inference rests on indirect reasoning from circulating steroid patterns, not on direct tissue or enzyme-level measurement. For clinicians, the practical takeaway is that the hormonal landscape around cannabis use is more textured than a single testosterone value reveals, but we do not yet know if these patterns have any downstream clinical consequence.

From a pharmacological standpoint, clinicians should note that the study does not address whether different cannabinoid profiles (THC-dominant versus CBD-dominant products, for example) produce different steroid signatures, nor does it examine potential interactions with exogenous testosterone, 5-alpha-re

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care